Regeneron Pharmaceuticals (XSWX:REGN) Purchase Of Business : CHF0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Regeneron Pharmaceuticals Purchase Of Business?

Regeneron Pharmaceuticals's purchase of business for the three months ended in Mar. 2024 was CHF0 Mil. It means Regeneron Pharmaceuticals spent CHF0 Mil on purchasing business. Regeneron Pharmaceuticals's purchase of business for the trailing twelve months (TTM) ended in Mar. 2024 was CHF0 Mil.

Compared with last quarter (CHF0 Mil in Dec. 2023 ), Regeneron Pharmaceuticals spent the same money on purchasing business in Mar. 2024 (CHF0 Mil).

Regeneron Pharmaceuticals Purchase Of Business Historical Data

The historical data trend for Regeneron Pharmaceuticals's Purchase Of Business can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Purchase Of Business Chart

Regeneron Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Purchase Of Business

Get a 7-Day Free Trial

-214.55

-47.48

Regeneron Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Purchase Of Business	Get a 7-Day Free Trial															-	-	-	-	-

Regeneron Pharmaceuticals Purchase Of Business Calculation

The amount used to purchase business.

Purchase Of Business for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF0 Mil.

Regeneron Pharmaceuticals Purchase Of Business Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Purchase Of Business provided by GuruFocus.com. Please click on the following links to see related term pages.

Regeneron Pharmaceuticals (XSWX:REGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (XSWX:REGN) » Definitions » Purchase Of Business

Comparable Companies

Traded in Other Exchanges

REGN:USA REGN:Mexico RGO:Germany REGN34:Brazil

Address

777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707

Website

https://www.regeneron.com

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).